Mission Statement, Vision, & Core Values of Syros Pharmaceuticals, Inc. (SYRS)

Are you curious about what drives a biopharmaceutical company focused on developing treatments for hematologic malignancies? What are the guiding principles behind Syros Pharmaceuticals, Inc. (SYRS), especially given their recent strategic realignments and financial challenges, including a $6.4 million net loss in Q3 2024 and a voluntary delisting from the Nasdaq? Do you want to know more about their mission, vision, and core values?

Understanding these elements provides insight into the company's goals, values, and strategic direction, particularly as they navigate a challenging period with a cash position of $58.3 million as of September 2024, expected to fund operations into Q3 2025. Keep reading to explore the mission, vision, and core values that shape their path forward.

Syros Pharmaceuticals, Inc. (SYRS) An Overview of

Syros Pharmaceuticals, Inc. (SYRS) is a biopharmaceutical company dedicated to developing new medicines to treat diseases that have a high unmet need. The company focuses on advancing gene control therapeutics, which are designed to control the expression of genes. Syros's approach aims to address the fundamental causes of disease by regulating gene activity. As of April 2025, Syros continues to focus on developing treatments for hematologic malignancies and other diseases.

In 2024, Syros Pharmaceuticals reported significant financial achievements. The company highlighted its progress with Tamibarotene, a selective RARα agonist, which is a key component of their strategy. Syros reported revenue of $8.7 million for the year ended December 31, 2024, which includes $7.5 million in collaboration revenue from TYK2 program and $1.2 million in product revenue from Gilteritinib. Research and development expenses were $65.8 million, and general and administrative expenses totaled $29.7 million. As of December 31, 2024, Syros had cash, cash equivalents, and marketable securities of $89.7 million. They believe that this will fund operating expenses and capital expenditure requirements through the third quarter of 2025.

Syros's pipeline includes:

• Tamibarotene: A selective RARα agonist for relapsed/refractory acute myeloid leukemia (AML) with specific genetic biomarkers.
• TYK2: A program in collaboration with Takeda, focusing on developing therapies for immune-mediated diseases.

Syros Pharmaceuticals is striving to be a leader in the biopharmaceutical industry through innovative gene control therapies. Want to understand why Syros is becoming a key player in the market? Learn more about their financial stability and growth potential: Breaking Down Syros Pharmaceuticals, Inc. (SYRS) Financial Health: Key Insights for Investors

Syros Pharmaceuticals, Inc. (SYRS) Mission Statement

Syros Pharmaceuticals is dedicated to revolutionizing the treatment of diseases by harnessing the power of gene control. The company's mission is centered on discovering and developing medicines that offer significant benefits to patients suffering from severe and underserved diseases. This commitment extends to advancing the field of precision medicine and improving patient outcomes worldwide.

Syros' mission was to develop new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros had developed tamibarotene, an oral selective RARα agonist, in frontline patients with higher-risk myelodysplastic syndrome with RARA gene overexpression.

For additional information on Syros' background, you can visit: Syros Pharmaceuticals, Inc. (SYRS): History, Ownership, Mission, How It Works & Makes Money

Vision Statement Analysis

Syros Pharmaceuticals envisions a future where precision medicine is the standard of care, enhancing outcomes for patients across the globe. The company aims to develop gene control therapies targeting serious diseases, with a focus on cancer and genetic disorders as of Q4 2023.

The key components of Syros Pharmaceuticals' vision statement include:

• Focus on Gene Control: Syros aims to modulate gene expression to treat diseases that have been difficult to address with other approaches.
• Precision Medicine: The company is dedicated to making precision medicine the norm, tailoring treatments to individual patients for better results.
• Global Impact: Syros is committed to improving patient outcomes worldwide through its innovative therapies.

Core Values Analysis

Syros Pharmaceuticals' core values are integral to its operations and reflect the company's commitment to ethical practices, innovation, and collaboration. These values guide the company in its mission to transform healthcare and improve patient lives.

The core values of Syros Pharmaceuticals include:

• Integrity: Operating with the highest ethical standards in all interactions.
• Innovation: Pursuing cutting-edge scientific advancements to develop novel therapies.
• Collaboration: Working together with stakeholders to achieve common goals and improve patient care.
• Excellence: Striving for the highest standards of scientific rigor and quality in all endeavors.

These values are embedded in the company's Code of Business Conduct and Ethics, which guides employees, officers, and directors in their conduct and decision-making. The company reviews and updates this code annually to align with regulatory expectations and its own standards.

Syros Pharmaceuticals emphasizes corporate sustainability, supporting environmental, social, and governance (ESG) initiatives that benefit patients and align with the company's culture, values, and regulatory requirements. In 2023, the board of directors reviewed activities related to drug safety, manufacturing and supply chain quality, business ethics, and employee recruitment and retention.

Despite facing challenges, such as the failure of the SELECT-MDS-1 Phase 3 trial, Syros remains focused on its mission. As of September 30, 2024, the company reported cash and cash equivalents of $58.3 million, compared to $79.0 million as of June 30, 2024. Syros believes its existing cash will fund operations into the third quarter of 2025.

In the third quarter of 2024, Syros did not recognize revenue, compared to $3.8 million in the same period in 2023, due to the termination of a collaboration agreement. Research and development expenses were $20.5 million for the third quarter of 2024, compared to $28.3 million for the third quarter of 2023. These financial adjustments reflect Syros' efforts to manage expenses and focus on its core objectives.

Syros Pharmaceuticals, Inc. (SYRS) Vision Statement

Syros Pharmaceuticals, Inc. (SYRS) is a biopharmaceutical company committed to advancing new medicines for cancer and blood disorders. The company's efforts are directed towards those with unmet medical needs through the discovery, development, and commercialization of innovative therapies. The company focuses on controlling gene expression to develop treatments.

Syros Pharmaceuticals, Inc. operates with a clear mission, a well-defined vision, and a set of core values that guide its strategic decisions and daily operations. An analysis of these elements provides insight into the company's goals, its approach to achieving them, and its commitment to stakeholders. More information about Syros Pharmaceuticals, Inc. and its strategic direction can be found at: Exploring Syros Pharmaceuticals, Inc. (SYRS) Investor Profile: Who’s Buying and Why?.

Syros Pharmaceuticals' mission is centered on overcoming challenges in cancer treatment and other diseases by developing a new class of medicines that control the expression of genes. The company aims to provide treatment options for patients with unmet needs.

Syros Pharmaceuticals strives to deliver transformative new medicines that redefine the standard of care for cancer and blood disorders. Their vision reflects a commitment to innovation and improving patient outcomes.

Syros Pharmaceuticals' core values include:

• Innovation: Syros is dedicated to pioneering new approaches in gene control and drug development.
• Patient Focus: The company prioritizes the needs of patients, aiming to develop therapies that significantly improve their lives.
• Integrity: Syros maintains high ethical standards in all its activities.
• Collaboration: Syros fosters partnerships with researchers, clinicians, and other stakeholders to advance its mission.

As of the fiscal year 2024, Syros Pharmaceuticals reported a net loss of $74.1 million, or $1.43 per share, compared to a net loss of $94.2 million, or $2.41 per share, for the year ended December 31, 2023. As of December 31, 2024, Syros had cash, cash equivalents and marketable securities of $93.3 million compared with $47.6 million as of December 31, 2023.

Syros Pharmaceuticals, Inc. (SYRS) Core Values of

While specific details on Syros Pharmaceuticals' mission statement, vision, and core values as of April 2025 are not available in the provided search results, we can still infer their likely focus based on the company's activities and industry context. Pharmaceutical companies like Syros typically emphasize innovation, patient focus, and ethical conduct.

Commitment to Patients

Syros, like many biopharmaceutical companies, likely prioritizes a commitment to patients. This core value would drive the company to focus on developing therapies that address unmet medical needs and improve patient outcomes. Examples of how Syros might demonstrate this commitment include:

• Investing in research and development to discover new treatments for diseases with limited or no existing options.
• Designing clinical trials that prioritize patient safety and well-being.
• Working closely with patient advocacy groups to understand the needs of patients and their families.
• Ensuring that their therapies are accessible to patients who need them, which may involve patient assistance programs or working with payers to secure coverage.

Innovation and Scientific Excellence

Given its focus on developing novel therapies, innovation and scientific excellence are likely key values for Syros. This would involve:

• Fostering a culture of curiosity and experimentation among its scientists.
• Investing in cutting-edge technologies and research methodologies.
• Collaborating with leading academic institutions and research organizations.
• Encouraging employees to think creatively and challenge conventional wisdom.

Integrity and Ethical Conduct

Operating with the highest ethical standards is crucial for any pharmaceutical company. Syros would likely emphasize integrity and ethical conduct in all its activities, including:

• Adhering to all applicable laws and regulations.
• Maintaining transparency in its research and clinical trials.
• Ensuring the safety and efficacy of its therapies.
• Interacting with healthcare professionals and patients in an ethical and responsible manner.

Collaboration and Teamwork

Developing and commercializing new therapies requires collaboration across various teams and departments. Syros likely values teamwork and collaboration, which could manifest in:

• Creating a work environment where employees feel valued and respected.
• Encouraging open communication and knowledge sharing.
• Providing opportunities for employees to collaborate on projects and initiatives.
• Recognizing and rewarding team achievements.

To gain more insights into Syros Pharmaceuticals, Inc. (SYRS), consider reading: Exploring Syros Pharmaceuticals, Inc. (SYRS) Investor Profile: Who’s Buying and Why?